PI3K activation promotes resistance to eribulin in HER2-negative breast cancer

BACKGROUND: Eribulin is a microtubule-targeting agent approved for the treatment of advanced or metastatic breast cancer (BC) previously treated with anthracycline- and taxane-based regimens. PIK3CA mutation is associated with worse response to chemotherapy in oestrogen receptor-positive (ER+)/human...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Gris-Oliver, Albert, Ibrahim, Yasir H., Rivas, Martín A., García-García, Celina, Sánchez-Guixé, Mònica, Ruiz-Pace, Fiorella, Viaplana, Cristina, Pérez-García, José M., Llombart-Cussac, Antonio, Grueso, Judit, Parés, Mireia, Guzmán, Marta, Rodríguez, Olga, Anton, Pilar, Cozar, Patricia, Calvo, Maria Teresa, Bruna, Alejandra, Arribas, Joaquín, Caldas, Carlos, Dienstmann, Rodrigo, Nuciforo, Paolo, Oliveira, Mafalda, Cortés, Javier, Serra, Violeta
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8076303/
https://ncbi.nlm.nih.gov/pubmed/33723394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-021-01293-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars